Pharmacyclics Inc (PCYC)

PCYC (:Drugs) EQUITY
$261.25
pos +1.70
+0.66%
Today's Range: 260.76 - 261.68 | PCYC Avg Daily Volume: 1,317,600
Last Update: 05/22/15 - 4:00 PM EDT
Volume: 1,953,837
YTD Performance: 0.00%
Open: $260.76
Previous Close: $259.55
52 Week Range: $82.51 - $261.68
Oustanding Shares: 77,079,177
Market Cap: 20,136,934,991
6-Month Chart
TheStreet Ratings Grade for PCYC
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 1 2 2 7
Moderate Buy 0 0 0 0
Hold 9 10 10 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.80 2.67 2.67 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
PCYC Sector Avg. S&P 500
0.00 290.20 26.87
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 180.50 87.63 3.39
Net Income 28.50 -3.45 0.00
EPS 26.80 -2.93 0.00
Earnings for PCYC:
EBITDA 0.13B
Revenue 0.73B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $-0.62 $0.12 $0.08 $4.76
Number of Analysts 7 7 8 8
High Estimate $0.22 $0.79 $1.18 $7.96
Low Estimate $-1.36 $-0.32 $-1.24 $2.45
Prior Year $-0.49 $0.53 $1.09 $0.08
Growth Rate (Year over Year) -27.11% -78.17% -92.43% 5,665.15%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Acquisitions cut into overabundance of companies.
Many of these stocks are off to the races.
It's not the Fed chief's place.

Earnings Growth Boosts AbbVie Real Money Pro($)

Drug franchises are still going strong.
The ecstasy and the agony of M&A all in one day.
Combined Heinz-Kraft heads a long second-quarter list.
You can't help but feel better about both groups.
If there is no catalyst, I'd join those who sell on a bounce.
This sector could see some real damage.

Columnist Conversations

Ford continues to underwhelm. The stock has been in a steady drift lower since its March 23rd high. This...
This past week, 10-year YIELD broke and sustained below key support at 2.18% - 2.15%, and has continued lower ...
Eli Lilly is trading at new 52 week highs today. The drug manufacturer is up over 3.25% and is near the to...
On May 15 and 18 I mentioned here about adding some Jun 29 calls, our price was 1.75. The chart was outstandi...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.